DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CURRICULUM VITAE Ann C. Childress, M.D. Personal Data: Office Address: Center for Psychiatry and Behavioral Medicine, Inc 7351 Prairie Falcon Rd, Suites 150 & 160 Las Vegas, NV 89128 Office Telephone: 702-838-0742 Military Service: Lieutenant Colonel (sel) United States Air Force September 1992-September 1998 Honorable Discharge Employment: April 2004 – Present Psychiatrist and President Center for Psychiatry and Behavioral Medicine, Inc 7351 Prairie Falcon Rd, Suites 150 & 160 Las Vegas, NV 89128 June 2014 – Present Adjunct Associate Professor Touro University Nevada 874 American Pacific Drive Henderson, NV 89014 March 2003 –2018 Staff Psychiatrist Spring Mountain Treatment Center 7000 W. Spring Mountain Rd. Las Vegas, NV 89117 January 2012 – Present Courtesy Staff Psychiatrist July 2002 – July 2008 Montevista Hospital 5900 W. Rochelle Avenue Las Vegas, NV 89103 April 2001 - Present Adjunct Faculty University of Nevada School of Medicine Reno, NV Jan 2019 – Present Clinical Associate Professor Dept. of Family Medicine University of Nevada Las Vegas School of Medicine Las Vegas, NV Page 2 Employment (cont.): April 2001 –August 2004 Psychiatrist and Vice President Nevada Behavioral Health, Inc 2055 West Charleston Blvd, Suite B Las Vegas, NV 89102 October 1998 – 2008 Staff Psychiatrist - University Medical Center 800 W. Charleston Blvd Las Vegas, NV 89102 October 1998 - March 2001 Assistant Professor and Vice-Chairman University of Nevada School of Medicine Department of Psychiatry Las Vegas, NV July 1996 - September 1998 Chief, Mental Health 99th Medical Group Nellis Air Force Base, NV March 1996 - July 1996 Chief, Outpatient Mental Health 96th Medical Group Eglin Air Force Base, FL January 1994 - July 1996 Chief, Mental Health Consultation and Liaison Residency Education Representative 96th Medical Group Eglin Air Force Base, FL October 1992 - July 1996 Psychiatrist 96th Medical Group Eglin Air Force Base, FL January 1993 - July 1996 Member, Consulting Board of Trustees Rivendell Psychiatric Hospital Ft. Walton Beach, FL August 1991 - July 1992 Courtesy Staff Psychiatrist Coastal Carolina Hospital Conway, SC Page 3 Education and Professional Training: July 1990 - June 1992 Fellowship, Child and Adolescent Psychiatry Medical University of South Carolina Charleston, SC July 1988 - June 1990 Resident in Psychiatry Medical University of South Carolina June 1988 Completed Internship in Psychiatry Medical University of South Carolina June 1987 Doctor of Medicine (M.D.) Medical University of South Carolina June 1985 Completed Basic Sciences St. Louis University School of Medicine St. Louis, MO May 1983 Bachelor of Arts (B.A.) Washington University St. Louis, MO Majors: Chemistry, Biology Board Certification and Licensure: June 1988 South Carolina License #13976 (currently inactive) February 1997 Nevada License #8091 January 1993 American Board of Psychiatry and Neurology (ABPN) Certificate #36745 October 1993 ABPN Child and Adolescent Psychiatry Certificate #3197 January 2000 –2004 Examiner for ABPN Adult Psychiatry Child & Adolescent Psychiatry Professional Societies: American Psychiatric Association (Fellow) American Academy of Child and Adolescent Psychiatry American Professional Society of ADHD and Related Disorders Nevada Psychiatric Association Honors and Awards: Page 4 July 1992 Child Psychiatry Research Award Medical University of South Carolina June 1991 Benjamin C. Riggs Award "Best Resident Paper 1990-1991" Department of Psychiatry Medical University of South Carolina May 1987 Alpha Omega Alpha Medical University of South Carolina Charleston, South Carolina August 1983 - May 1987 Health Professions Scholarship St. Louis University School of Medicine Medical University of South Carolina May 1983 Phi Beta Kappa Cum Laude R.O.T.C. Distinguished Graduate Washington University August 1979 - May 1983 R.O.T.C. Scholarship Washington University Publications: Childress AC, Komolova M, Sallee RF. An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. Expert Opin Drug Metab Toxicol. 2019. [Epub ahead of print.] Childress AC, Chow H. Amphetamine extended-release oral suspension for attention- deficit/hyperactivity disorder. Expert Rev Clin Pharmacol. 2019;12:965-971. Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings. J Child Adolesc Psychopharmacol. 2019. [Epub ahead of print.] Childress AC, Kando JC, King TR, Pardo A, Herman BK. Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2019;29:2-8. Publications (cont.): Page 5 Childress AC, Newcorn JH, Cutler AJ. Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder. Adv Ther. 2019;36:1370-1387. Wigal SB, Hopkins SC, Koblan KS, Childress A, Kent JM, Tsai J, Hsu J, Loebel A, Goldman R. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. J Atten Disord. 2019:1087054719864644. Faraone SV, Rostain AL, Blader J, Busch B, Childress AC, Connor DF, Newcorn JH. Practitioner Review: Emotional Dysregulation in Attention-Deficit/Hyperactivity Disorder - Implications for Clinical Recognition and Intervention. J Child Psychol Psychiatry. 2019;60:133-150. Engelking D, Childress AC, McMahen R, Sikes CR. How to Dose Attention- Deficit/Hyperactivity Disorder Medications Without a Grain of Salt. J Child Adolesc Psychopharmacol. 2018;28:576-577. Abbas R, Childress AC, Nagraj P, Rolke R, Berry SA, Palumbo DR. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole. Clin Ther. 2018;40:733-740. Wigal SB, Childress A, Berry SA, Belden HW, Chappell P, Wajsbrot DB, Nagraj P, Abbas R, Palumbo D. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2018;28:314-321. Childress AC, Wigal SB, Brams MN, Turnbow JM, Pincus Y, Belden HW, Berry SA. Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018;28:306-313. Childress AC, Stark JG. Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Preschool-Aged Children. J Child Adolesc Psychopharmacol. 2018;28:606-614. Childress A, Ponce De Leon B, Owens M. QuilliChew extended-release chewable tablets for the treatment of ADHD in patients ages 6 years old and above. Expert Opin Drug Deliv. 2018;15:1263-1270. Weiss M, Childress A, Nordbrock E, Adjei AL, Kupper RJ, Mattingly G. Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. J Clin Med. 2019;8. Page 6 Publications (cont.): Wigal T, Childress A, Frick G, Yan B, Wigal S, Madhoo M. Effects of SHP465 Mixed Amphetamine Salts in Adults with ADHD in a Simulated Adult Workplace Environment. Postgrad Med. 2018 Jan;130(1):111-121. Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):10-18. Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended- Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014. Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo- Controlled Study. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):19-28. Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct;27(8):690-699. Childress A, Stark JG, McMahen R, Engelking D, Sikes C. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults. Clin Pharmacol Drug Dev. 2018 Feb;7(2):151-159. Childress A. The Safety of Extended-Release Drug Formulations for the Treatment of ADHD. Expert Opin Drug Saf. 2017 May;16(5):603-615. Childress A, Belchenko D, Lempa B. The Use of Modified-Release Methylphenidate in the Treatment of Attention-Deficit/Hyperactivity Disorder. Expert Rev Neurother. 2017 Feb;17(2):113-121. Wigal SB, Wigal T, Childress A, Donnelly GAE, Reiz JL. The Time Course of Effect of Multilayer-Release Methylphenidate Hydrochloride Capsules: A Randomized, Double-Blind Study of Adults With ADHD in a Simulated Adult Workplace Environment. J Atten Disord. 2016 Oct 1. [Epub ahead of print] Publications
Recommended publications
  • Nicotinic Receptors in Neurodegeneration

    Nicotinic Receptors in Neurodegeneration

    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Joel L. Young, M.D

    Joel L. Young, M.D

    Joel L. Young, M.D. 441 South Livernois Road, Suite 100 Rochester Hills, Michigan 48307 Phone: 248-608-8800 / Fax: 248-608-2490 / E-mail: [email protected] Professional History 2000 – Present: Chief Medical Officer and Founder, Clinical Trials Group at the Rochester Center for Behavioral Medicine, Rochester Hills, MI 1993 – Present: Medical Director and Founder, Rochester Center for Behavioral Medicine, Rochester Hills, MI (www.rcbm.net). 2008 (Current): Clinical Associate Professor of Psychiatry, Wayne State University, Detroit, MI. 2000 – 2007: Medical Director, Crittenton Network for Behavioral Health, Rochester, MI. 2000 – 2002: Chief of Staff, Department of Psychiatry, Crittenton Hospital, Rochester, MI. July, 1993 – 1997: Medical Director, Psychiatric Emergency Services, Crittenton Hospital. July, 1992 – June, 1993: Chief Resident of Adult Services, Department of Psychiatry, University of Michigan Hospitals, Ann Arbor, MI. Oct. 1991-Sept. 1993: Unit Psychiatrist, Bon Secours Adolescent Mental Health Unit, Grosse Pointe, MI. August, 1991 – 1996: Consulting Psychiatrist, Beacon Hill Clinic, Birmingham, MI. July, 1991 – June, 1992: Consulting Psychiatrist, Washtenaw County Community Mental Health Services, Ann Arbor, MI. July, 1990 – June, 1992: House Officer, Department of Psychiatry, University of Michigan Hospitals. June, 1989 – June, 1990: Intern, Departments of Internal Medicine, Pediatrics and Psychiatry, University of Michigan Hospitals. Boards 2018 Fellow: American Board of Psychiatry and Neurology 2017 Re-certification of Geriatric Qualifications by the American Board of Psychiatry and Neurology through 2027. 2017 Re-certification of Forensic Qualifications by the American Board of Psychiatry and Neurology through 2027 2014 Re-Certification by the American Board of Psychiatry and Neurology 2007 Re-certification by the American Board of Adolescent Psychiatry.
  • Supported by an Educational Grant from Sunovion Pharmaceuticals Inc. Faculty

    Supported by an Educational Grant from Sunovion Pharmaceuticals Inc. Faculty

    Supported by an educational grant from Sunovion Pharmaceuticals Inc. Faculty Leslie Citrome, MD, MPH C. Brendan Montano, MD Clinical Professor of Psychiatry and CT Clinical Research Behavioral Sciences Director, Principal Investigator New York Medical College Private Practice, Internal Medicine Valhalla, New York Cromwell, Connecticut Faculty Disclosure • Dr. Citrome: Consultant—Acadia, Alkermes, Allergan, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda; Royalties—Springer Healthcare (book), UpToDate (reviewer), Wiley (Editor in Chief, International Journal of Clinical Practice); Shareholder (and spouse)—Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer; Speaker—Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva. • Dr. Montano: Consultant—Allergan, Shire/Takeda Pharmaceutical Company Ltd., Sunovion Pharmaceuticals Inc., Arbor Pharmaceuticals Ltd.; Research Support—Allergan, Avanir, Sunovion Pharmaceuticals Inc., Tonix, BioHaven, Axsome Therapeutics, Arbor Pharmaceuticals Ltd.; Speakers Bureau— Allergan, Shire/Takeda Pharmaceutical Company Ltd., Arbor Pharmaceutical Ltd. Disclosure • The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). – The off-label and investigational use of antidepressants, topiramate,
  • Horizon Scanning Status Report June 2019

    Horizon Scanning Status Report June 2019

    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T

    WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
  • Treatment-Resistant Attention-Deficit Hyperactivity Disorder: Clinical

    Treatment-Resistant Attention-Deficit Hyperactivity Disorder: Clinical

    Review Treatment-resistant Attention-deficit Hyperactivity Disorder: Clinical Significance, Concept, and Management Mu‑Hong Chen, M.D., Ph.D.1,2, Kai‑Lin Huang, M.D.1,2, Ju‑Wei Hsu, M.D.1,2,*, Shih‑Jen Tsai, M.D.1,2,* 1Department of Psychiatry, Taipei Veterans General Hospital, 2Division of Psychiatry, School of Medicine, National Yang‑Ming University, Taipei, Taiwan Abstract Background: Attention-deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neurodevelopmental disorder known to cause impairment across the lifespan. ADHD was ranked as approximately the 50th leading cause of global years lived with disability for children, coming in ahead of diabetes, meningitis, and intellectual disability. About 20%–40% of patients with ADHD would not achieve the treatment response and symptomatic remission, increasing future risks of substance abuse, suicidal behavior, and premature mortality. However, there is no standard consensus for defining treatment resistance in ADHD.Method: In this systematic review, we intend to focus on treatment-resistant ADHD in the aspects of disease definition, psychopathology, pathophysiology, and treatment. Results: We suggest that the more ideal strategy of defining treatment resistance should consider the improvement of ADHD symptoms and the global functioning simultaneously. Psychiatric comorbidities (i.e. destructive behavior disorders and mood disorders), physical comorbidities (i.e. epilepsy), and psychosocial adversities (i.e. parental psychopathology and poor family functioning) should be the first to be assessed in the evaluation of treatment response or resistance. The optimal medication adjustment or the combination of medications and psychotherapy may be the potential therapeutic strategy for treatment-resistant ADHD. Conclusion: Further studies would be necessary to elucidate the underlying mechanisms of treatment-resistant ADHD and to research the novel treatment strategies for ADHD.
  • Rxoutlook® 1St Quarter 2019

    Rxoutlook® 1St Quarter 2019

    ® RxOutlook 1st Quarter 2020 optum.com/optumrx a RxOutlook 1st Quarter 2020 Orphan drugs continue to feature prominently in the drug development pipeline In 1983 the Orphan Drug Act was signed into law. Thirty seven years later, what was initially envisioned as a minor category of drugs has become a major part of the drug development pipeline. The Orphan Drug Act was passed by the United States Congress in 1983 in order to spur drug development for rare conditions with high unmet need. The legislation provided financial incentives to manufacturers if they could demonstrate that the target population for their drug consisted of fewer than 200,000 persons in the United States, or that there was no reasonable expectation that commercial sales would be sufficient to recoup the developmental costs associated with the drug. These “Orphan Drug” approvals have become increasingly common over the last two decades. In 2000, two of the 27 (7%) new drugs approved by the FDA had Orphan Designation, whereas in 2019, 20 of the 48 new drugs (42%) approved by the FDA had Orphan Designation. Since the passage of the Orphan Drug Act, 37 years ago, additional regulations and FDA designations have been implemented in an attempt to further expedite drug development for certain serious and life threatening conditions. Drugs with a Fast Track designation can use Phase 2 clinical trials to support FDA approval. Drugs with Breakthrough Therapy designation can use alternative clinical trial designs instead of the traditional randomized, double-blind, placebo-controlled trial. Additionally, drugs may be approved via the Accelerated Approval pathway using surrogate endpoints in clinical trials rather than clinical outcomes.
  • ADHD Investor Event Presentation

    ADHD Investor Event Presentation

    ADHD Investor Event October 11, 2018 Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain and maintain regulatory approvals for our product candidates, including expectations about our ability to use the 505(b)(2) pathway and expedited FDA review, the clinical utility of our product candidates and our intellectual property position. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. These and other risks concerning our business are described in additional detail in our Quarterly Report on Form 10-Q filed with the SEC on August 10, 2018, and our other Periodic and Current Reports filed with the SEC. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law.
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders

    Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders

    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
  • Activities of Nicotinic Acetylcholine Receptors Modulate Neurotransmission and Synaptic Architecture

    Activities of Nicotinic Acetylcholine Receptors Modulate Neurotransmission and Synaptic Architecture

    NEURAL REGENERATION RESEARCH December 2014,Volume 9,Issue 24 www.nrronline.org INVITED REVIEW Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture Akira Oda1, Hidekazu Tanaka2 1 CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-26-1, Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan 2 Laboratory of Pharmacology, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1, Noji-higashi, Kusatsu, Shiga 525-8577, Japan Abstract Corresponding author: The cholinergic system is involved in a broad spectrum of brain function, and its failure has Hidekazu Tanaka, M.D., Ph.D., been implicated in Alzheimer’s disease. Acetylcholine transduces signals through muscarinic Laboratory of Pharmacology, Department and nicotinic acetylcholine receptors, both of which influence synaptic plasticity and cognition. of Biomedical Sciences, College of Life However, the mechanisms that relate the rapid gating of nicotinic acetylcholine receptors to per- Sciences, Ritsumeikan University, sistent changes in brain function have remained elusive. Recent evidence indicates that nicotinic [email protected]. acetylcholine receptors activities affect synaptic morphology and density, which result in per- sistent rearrangements of neural connectivity. Further investigations of the relationships between doi:10.4103/1673-5374.147943 nicotinic acetylcholine receptors and rearrangements of neural circuitry in the central nervous http://www.nrronline.org/ system may help understand the pathogenesis of Alzheimer’s disease. Accepted: 2014-11-03 Key Words: cholinergic system; nicotinic acetylcholine receptors (nAChRs); Alzheimer’s disease (AD); synaptic transmission; synaptic plasticity; synaptic morphology; dendritic spine remodeling; cognition Funding: Tanaka H is supported by the Takeda Science Foundation and JSPS KAKENHI Grant Number 19590247.